InvestorsHub Logo
Followers 34
Posts 4311
Boards Moderated 0
Alias Born 07/16/2014

Re: nidan7500 post# 247876

Saturday, 04/25/2020 9:59:51 AM

Saturday, April 25, 2020 9:59:51 AM

Post# of 464022
The beauty and also possibly the weakness of the strategy (if that’s what they are trying) imho will be proving that A2-73 is the reason for the improvements and not that they just figured out which patients are most likely to benefit from donepezil because it also binds to S1.

It could depend on how many patients in the current trial are only taking A2-73 w/o also taking one of the other SOC’s.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News